Preclinical safety evaluation of inhaled cyclosporine in propylene glycol

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 20, Issue 4, 2007, Pages 417-428

  Wang, Tao ^a,c   Noonberg, Sarah ^a   Steigerwalt, Ronald ^a   Lynch, Maryellen ^b   Kovelesky, Rosemary A ^a   Rodríguez, Carlos A ^a   Sprugel, Katherine ^a   Turner, Nancy ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

Aerosolized cyclosporine; Preclinical evaluation; Propylene glycol; Toxicity

Indexed keywords

CYCLOSPORIN; PROPYLENE GLYCOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG SAFETY; EVALUATION; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; MALE; MEDICAL NEBULIZER; NEBULIZATION; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; TOXICOKINETICS;

ADMINISTRATION, INHALATION; ANIMALS; CYCLOSPORINE; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MALE; PROPYLENE GLYCOL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 37549070685     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2007.0626     Document Type: Article

References (25)

1. OPTN registry database. Available from www.optn.org (accessed January, 2007).
2. Arcasoy, S.M., and R.M. Kotloff. 1999. Lung transplantation. N. Engl. J. Med. 340:1081-1091.
3. Hosenpud, J.D., L.E. Bennett, B.M. Keck, B. Fiol, M.M. Boucek, and R.J. Novick. 1999. The Registry of the International Society for Heart and Lung Transplantation: sixteenth official report - 1999. J. Heart Lung Transplant. 18:611-626.
4. Trulock, E.P. 1993. Management of lung transplant rejection. Chest 103:1566-1576.
5. Iacono, A.T., T.E. Corcoran, B.P. Griffith, W.F. Grgurich, D.A. Smith, A. Zeevi, G.C. Smaldone, K.R. McCurry, B.A. Johnson, and J.H. Dauber. 2004. Aerosol cyclosporine therapy in lung transplant recipients with bronchiolitis obliterans. Eur. Respir. J. 23:384-390.
6. Iacono, A.T., B.A. Johnson, W.F. Grgurich, J.G. Youssef, T. E. Corcoran, D.A. Seiler, J.H. Dauber, G.C. Smaldone, A. Zeevi, S.A. Yousem, J.J. Fung, G.J. Burckart, K.R. McCurry, and B.P. Griffith. 2006. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N. Engl. J. Med. 354:141-150.
7. Blot, F., R. Tavakoli, S. Sellam, B. Epardeau, F. Faurisson, N. Bernard, M.H. Becquemin, I. Frachon, M. Stern, J.J. Pocidalo, C. Carbon, A. Bisson, and I. Caubarrère. 1995. Nebulized cyclosporine for prevention of acute pulmonary allograft rejection in the rat: pharmacokinetic and histologic study. J. Heart Lung Transplant. 14:1162-1172.
8. Dowling, R.D., M. Zenati, G.J. Burckart, S.A. Yousem, M. Schaper, R.L. Simmons, R.L. Hardesty, and B.P. Griffith. 1990. Aerosolized cyclosporine as single-agent immunotherapy in canine lung allografts. Surgery 108:198-205.
9. Keenan, R.J., A.J. Duncan, S.A. Yousem, M. Zenati, M. Schafer, R.D. Dowling, Y. Alarie, G.J. Burckart, and B.P. Griffith. 1992. Improved immunosuppresion with aerosolized cyclosporine in experimental pulmonary transplantation. Transplantation 53:20-25.
10. Mitruka, S., S.M. Pham, A. Zeevi, S. Li, J. Cai, G.J. Burckart, S. A. Yousem, R.J. Keenan, and B.P. Griffith. 1998. Aerosol cyclosporine prevents acute allograft rejection in experimental lung transplantation. J. Thorac. Cardiovasc. Surg. 115:28-37.
11. Zenati, M., A.J. Duncan, G.J. Burckart, M. Schaper, S.A. Yousem, B.P. Griffith, and D. Casarotto. 1991. Immunosuppression with aerosolized cyclosporine for prevention of lung rejection in a rat model. Eur. J. Cardiothorac. Surg. 5:266-272.
12. Cannon, W.C., E.F. Blanton, and K.E. McDonald. 1983. The flow-past chamber: an improved nose-only exposure system for rodents, Am. Ind. Hyg. Assoc. 44:923-928.
13. Cuddihy, R.G., D.G. Brownstein, O.G. Rabbe, and G.M. Kanapilly. 1973. Respiratory tract deposition of polydispersed aerosols in beagle dogs. J. Aerosol Sci. 4:35-45.
14. Schlesinger, R.B. 1985. Comparative deposition of inhaled aerosols in experimental animals and humans: a review. J. Toxicol. Envion. Health 15:197-214.
15. Sangalli L., A. Bortolotti, L. Jiritano, and M. Bonati. 1988. Cyclosporine pharmacokinetics in rats and interspecies: comparison in dogs, rabbits rats, and humans. Drug Metab. Dispos. 16:749-753.
16. Mason, J. 1989. Pharmacology of cyclosporine (sandimmune) VII. Pathophysiology and toxicology of cyclosporine in humans and animals. Pharm. Rev. 42:1423-1434.
17. Miller, L.W. 2002. Cardiovascular toxicities of immunosuppressive agents. Am. J. Transplant. 2:807-818.
18. Thomson, A.W., P.H. Whiting, and J.G. Simpson. 1984. Cyclosporine: immunology, toxicity and pharmacology in experimental animals. Agents Actions 15:306-327.
19. Burckart, G.J., G.C. Smaldone, M.A. Eldon, R. Venkataramanan, J. Dauber, A. Zeevi, K. McCurry, T.P. McKaveney, T.E. Corcoran, B.P. Griffith, and A.T. Iacono. 2003. Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. Pharm. Res. 20:252-256.
20. Cosmetic Ingredient Review Expert Panel. Final report on the safety assessment of propylene glycol and polypropylene glycols. 1994. J. Am. Coll. Toxicol. 13:437-491.
21. LaKind, J.S., E.A. McKenna, R.P. Hubner, and R.G. Tardiff. 1999. A review of the comparative mammalian toxicity of ethylene glycol and propylene glycol. Crit. Rev. Toxicol. 29:331-365.
22. Miller, R.R, E.A. Hermann, J.T. Young, T.D. Landry, and L.L. Calhoun. 1984. Ethylene glycol monomethyl ether and propylene glycol monomethyl ether: metabolism, disposition, and subchronic inhalation toxicity studies. Environ. Health Perspect. 57:233-239.
23. Motoyoshi, K., S. Nozawa, M. Yoshirmura, and K. Matsuda. 1984. The safety of propylene glycol and other humectants. Cosmet. Toilet 99:83-91.
24. Ruddick, J.A. 1972. Toxicology, metabolism and biochemistry of 1,2-propanediol. Toxicol. Appl. Pharmacol. 21:102-111.
25. Suber, R.L., R. Deskin, I. Nikiforov, X. Fouillet, and C.R. Coggins. 1989. Subchronic nose-only inhalation study of propylene glycol in Sprague-Dawley rats. Fd. Chem. Toxicol. 27:573-583.